Korea BMS Pharmaceutical Appoints Lee Hye-young as New CEO
[Asia Economy Reporter Lee Gwan-joo] Korea BMS Pharmaceutical announced on the 26th that Lee Hye-young has been appointed as the new CEO effective August 10.
CEO Lee, who graduated from Seoul National University College of Pharmacy and earned an MBA from Korea University, has accumulated diverse experience and expertise through various departments including marketing, strategic planning, business development, and clinical research during her over 20 years at Pfizer. Her roles included CEO of Pfizer Korea Upjohn, CEO of Pfizer Singapore, and head of the cardiovascular treatment division for the APAC region. She was appointed Vice President of Pfizer Korea in 2017 and returned to Korea, and in 2020, she was appointed CEO of Viatris Korea.
Along with her role as CEO of Korea BMS Pharmaceutical, CEO Lee will also oversee BMS's cardiovascular disease division for the Asia cluster.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Meanwhile, the former CEO Kim Jin-young has been promoted to lead the Global BMS Compliance and Ethics Division, overseeing compliance strategies for the Intercontinental region. The Intercontinental region includes Asia excluding Japan, Australia, New Zealand, South America, the Middle East, Africa, Eastern Europe, Turkey, Israel, and India.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.